Analysts Set Quince Therapeutics, Inc. (NASDAQ:QNCX) Target Price at $9.50

Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX - Get Free Report) have earned an average recommendation of "Buy" from the six brokerages that are covering the firm, MarketBeat.com reports. Four research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $9.50.

QNCX has been the topic of several analyst reports. Rodman & Renshaw initiated coverage on shares of Quince Therapeutics in a report on Tuesday, October 29th. They set a "buy" rating and a $11.00 price target on the stock. D. Boral Capital reiterated a "buy" rating and issued a $12.00 target price on shares of Quince Therapeutics in a research note on Wednesday, February 5th. Maxim Group started coverage on shares of Quince Therapeutics in a research note on Thursday, November 7th. They issued a "buy" rating and a $6.00 target price on the stock. RODMAN&RENSHAW upgraded shares of Quince Therapeutics to a "strong-buy" rating in a research note on Tuesday, October 29th. Finally, Brookline Capital Management began coverage on shares of Quince Therapeutics in a research note on Wednesday, December 18th. They issued a "buy" rating and a $9.00 target price on the stock.

Quince Therapeutics Stock Down 3.4 %

Quince Therapeutics stock traded down $0.05 during midday trading on Friday, hitting $1.40. 44,281 shares of the stock were exchanged, compared to its average volume of 127,744. Quince Therapeutics has a 52-week low of $0.51 and a 52-week high of $2.45. The stock has a market capitalization of $61.60 million, a price-to-earnings ratio of -1.13 and a beta of 0.61. The business's 50-day moving average price is $1.68 and its 200-day moving average price is $1.31. The company has a quick ratio of 9.53, a current ratio of 9.53 and a debt-to-equity ratio of 0.33.

Hedge Funds Weigh In On Quince Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of QNCX. Geode Capital Management LLC boosted its position in Quince Therapeutics by 10.9% during the 4th quarter. Geode Capital Management LLC now owns 375,932 shares of the company's stock valued at $703,000 after buying an additional 36,807 shares during the period. Shay Capital LLC raised its holdings in Quince Therapeutics by 60.8% in the 4th quarter. Shay Capital LLC now owns 276,799 shares of the company's stock worth $518,000 after purchasing an additional 104,616 shares in the last quarter. Scharf Investments LLC bought a new position in shares of Quince Therapeutics in the 4th quarter worth about $170,000. Northern Trust Corp increased its stake in shares of Quince Therapeutics by 48.5% in the 4th quarter. Northern Trust Corp now owns 50,524 shares of the company's stock worth $94,000 after acquiring an additional 16,501 shares in the last quarter. Finally, Two Sigma Investments LP bought a new position in shares of Quince Therapeutics in the 4th quarter worth about $57,000. Hedge funds and other institutional investors own 30.75% of the company's stock.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.